SlideShare a Scribd company logo
1 of 83
Download to read offline
1
CONTENTS
• Meaning
• Introduction
• Key function
• Agencies in INDIA
• Agencies in US
• Agencies in JAPAN
• Agencies in EU
• ICH
• References
2
MEANING OF DRUG REGULATION
• Drug
“All medicines for internal or external use of human beings or
animals and all substances intended to be used for diagnosis,
treatment, mitigation or prevention of any disease or disorder in
human beings or animals”
• Regulation
“To regulate means to control something so that it functions
properly”
3
INTRODUCTION
Drugs play an important role in the health of
both people and the economy of a country.
Pharmaceutical drugs are available from a large
number of sources.
4
INTRODUCTION
People and Governments willing to spend money on drugs
for many reasons so, it must be safe, effective and good
quality and used appropriately.
This means, in turn, that development, production,
importation, exportation and subsequent distribution of
drugs must be regulated to ensure that they meet
prescribed standards.
5
INTRODUCTION
• Therefore, effective drug regulation is required to ensure
the safety, efficacy and quality of drugs as well as
accuracy and appropriateness of the drug information
available to the public.
6
KEY FUNCTIONS OF DRUG REGULATORY AGENCY
 Product registration (drug evaluation and authorization,
and monitoring of drug efficacy and safety)
 Regulation of drug manufacturing, importation, and
distribution;
7
KEY FUNCTIONS OF DRUG REGULATORY AGENCY
 Regulation & Control of drug promotion and information.
 Adverse drug reaction (ADR) monitoring.
 Licensing of premises, persons and practices.
 Main goal of drug regulation is to guarantee the safety, efficacy
and quality of drugs available to public.
8
THE DRUG REGULATION CONSISTS OF:
1. Drug Laws
2. Drug Regulatory Agencies
3. Drug Regulatory Boards
4. Quality Control
5. Drug Information Centers etc.
9
DRUGS REGULATORY SYSTEM IN INDIA
10
Drugs and Health is in concurrent list of Indian Constitution
It is governed by both Centre and State Governments under
the Drugs & Cosmetics Act, 1940.
11
12
MAIN BODIES:MAIN BODIES:
* Central Drug Standard Control Organization (CDSCO)
* Ministry Of Health & Family Welfare (MHFW)
 Indian Council Of Medical Research (ICMR)
 Indian Pharmaceutical Association (IPA)
 Drug Technical Advisory Board (DTAB)
 Central Drug Testing Laboratory (CDTL)
 Indian Pharmacopoeia Commission (IPC)
 National Pharmaceutical Pricing Authority (NPPA)
INDIA – WELL DEFINED DRUG REGULATORY SYSTEM
GOVT. of INDIA
• Ministry of Health and Family Welfare
DGHS
CDSCO DCGI
13
DTAB
 Enforcement & GMP audit Div
 Quality Control Division – CDTL
 Registration Div
 New Drug Div
Pharmacovigilance
Trainings
APPROVAL OF INVESTIGATIONAL NEW DRUG
(IND)
14
15
CENTRAL LICENSING
16
16
17
17
18
Functions undertaken by Central GovernmentFunctions undertaken by Central Government
Statutory FunctionStatutory Function
1. Laying down standards of drugs, cosmetics, diagnostics and
devices.
2. Laying down regulatory measures, amendments to Acts and Rules.
3. To regulate market authorization of new drugs.
4. To regulate clinical research in India
19
1. To approve licenses to manufacture certain categories of drugs as
Central Licence Approving Authority i.e. for Blood Banks, Large
Volume Parenterals and Vaccines & Sera.
2. To regulate the standards of imported drugs.
3. Work relating to the Drugs Technical Advisory Board (DTAB) and
Drugs Consultative Committee (DCC).
4. Testing of drugs by Central Drugs Labs.
5. Publication of Indian Pharmacopoeia.
20
National Institute of Health and Family Welfare (NIHFW)
NIHFW is an Apex Technical Institute, funded by Ministry of Health
and Family Welfare, for promotion of health and family welfare
programmers in the country through education, training, research,
evaluation, consultancy and specialized services.
The NIHFW was established on March 9, 1977 by a merger of the
National Institute of Health Administration and Education (NIHAE)
with the National Institute of Family Planning (NIFP).
21
List of Governing Body Members of NIHFW
18 members
1 Chairman (ex-officio)
1 Vice Chairman (ex-officio)
9 Member ( ex-officio)
6 Member
1 Member Secretary (ex-officio)
22
ACTIVITIES AND RESPONSIBILITIESACTIVITIES AND RESPONSIBILITIES
 Measuring weight of children to assess the nutritional status.
 Assessment of diseases like level of anemia.
 Testing of food material like cooking salt for level iodine.
To release fund on the advice of the Ministry.
 It is responsible for all governmental programs relating to family
planning in India.
23
STRUCTURE AND ORGANIZATION
Union Health Minister
Governing Body
Scientific Advisory Board
Scientific
Advisory
Groups
Expert
Groups
Scientific
Advisory
Committee
Steering
Committee
Task Forces
24
ACTIVITIES AND RESPONSIBILITIESACTIVITIES AND RESPONSIBILITIES
 Extramural research is promoted by ICMR by establishing Centers
for Advanced Research in different research areas.
 The ICMR also funds task force studies which emphasize a time-
bound, goal-oriented approach.
25
 Open-ended research is conducted on the basis of applications for grants-in-aid
received from scientists in non-ICMR Research Institutes, Medical colleges and
Universities located in different parts of the country.
 In the context of the changing public health scene.
 Balancing of research efforts between different competing fields, especially
when resources are severely limited, is a typical problem encountered in the
management of medical research, particularly in developing countries.
26
DRUG TECHNICAL ADVISORY BOARD (DTAB)
The Central Government constitute a Board (to be called the Drugs
Technical Advisory Board) to advise the Central Government and
the State Governments on technical matters arising out of the
administration of D&C, Act 1940
The Board shall consist of the following members,
18 Members
10 ex-officio Members
5 Nominated Members
5 Elected Members
27
ACTIVITIES AND RESPONSIBILITIESACTIVITIES AND RESPONSIBILITIES
 It advices matter related to Drugs.
 The nominated and elected members of the Board shall hold office
for three years, but shall be eligible for re-nomination and re-
election.
 The Board may, subject to the previous approval of the Central
Government, make bye-laws fixing a quorum and regulating its
own procedure.
28
CENTRAL DRUG TESTING LABORATORY (CDTL)
 The central drug laboratory, Kolkata is national statutory
laboratory of the government of India for quality control of drug
and cosmetic and established under the D&C act ,1940.
 Oldest quality control laboratory of the drug control authorities in
India.
 Function under the director general of Health Services in the
Ministry of Health and Family Welfare.
29
FUNCTIONS UNDER TAKEN
Statutory Function:
 To Act as an Appellate authority.
 To function as Government Analyst for such states who do not have their
own testing facilities.
 Analytical quality control of majority of the imported drugs.
 Analytical quality control of drug formulations manufactured within the
country on behalf of the Central & State Drug standard control
organization
30
Other Functions
 Procurement, establishment, maintenance, storage and
distribution of I.P & International Reference standards.
 Preparation and standardization of I.P. reference standards against
USP, BP primary standards.
 To undertake analytical research in standardization and
methodology development of drug.
31
Indian
Pharmacopoeia
Commission
(IPC)
General Body
19 Members
Governing Body 10
Members
Scientific Body
23 Experts
CIPL
Lab
IPC
Secretariat
Indian Pharmacopoeia was prepared by Indian
Pharmacopoeia Commission(IPC)
32
ACTIVITIES AND RESPONSIBILITIES
 Development of comprehensive monographs.
 Accord priority to monographs of drugs included in the national
Essential Drug List and their dosage forms.
 Preparation of monograph for products that have normally been
in the market for not less than 2 years.
 Collaborate with pharmacopoeias like the BP, USP, JP and
International Pharmacopoeia with a view to harmonizing with
global standards.
33
DRUG REGULATORY AGENCIES IN US
34
AGENCIES
 The Food and Drug Administration (FDA)
 National Institutes of Health (NIH)
 Centers for Disease Control and Prevention
 Department of Health and Human Services (DHHS)
35
 Fed World - US Government Information
 National Center for Complementary and Alternative Medicine
(NCCAM)
 National Center for Infectious Diseases (NCID)
 National Library of Medicine
 National Science Foundation
 Office of Disease Prevention
36
The Food and Drug Administration (FDA) is an agency within the
U.S. Department of Health and Human Services. It consists of six
product centers, one research center, and two offices.
FDA’s responsibilities extend to the 50 United States, the District of
Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and
other U.S. territories and possessions.
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002
37
HISTORY
 1927 — The "Bureau of Chemistry" is reorganized into two separate
entities. Regulatory functions are located in the "Food, Drug, and
Insecticide Administration", and nonregulatory research is located
in the "Bureau of Chemistry and Soils".
 1930 — The name of the "Food, Drug, and Insecticide
Administration" is shortened to "Food and Drug Administration"
(FDA) under an agricultural appropriations act.
38
MISSION
 The Food and Drug Modernization Act states that the FDA has 4
roles:
To promote health by reviewing research and approving new
products
To ensure foods and drugs are safe and properly labeled
To work with other nations to “reduce the burden of regulation”
To cooperate with scientific experts and consumers to effectively
carry out these obligations
39
ORGANIZATION
 The agency currently has roughly 9,500 full-time employees and is
headquartered in Rockville, Maryland. The agency’s total budget in
financial year 2002 was about $1.4 billion (the federal government’s
financial year begins in September).
 The FDA is led by the Commissioner of Food and Drugs, who is appointed
by the President and confirmed by the Senate.
 Dr. Mark McClellan, a physician with a doctorate in economics, was
nominated to be commissioner by President George W. Bush in
September 2002 and confirmed by the Senate in October
40
41
FDA IS RESPONSIBLE FOR
 Protecting the public health by assuring that foods are safe, wholesome,
sanitary and properly labeled;
 Assuring human and veterinary drugs, and vaccines and other biological
products and medical devices intended for human use are safe and
effective
 Protecting the public from electronic product radiation
42
 Assuring cosmetics and dietary supplements are safe and properly labeled
 Regulating tobacco products
 Advancing the public health by helping to speed product innovations
 Helping the public get the accurate science-based information they need to use
medicines, devices, and foods to improve their health
 Initiation of a Recall. Includes voluntary, FDA requested, and FDA mandated.
43
What doesn’t FDA regulate?
FDA does not regulate:
 advertising (except for prescription drugs, medical devices, and
tobacco products)
 alcoholic beverages
 illegal drugs of abuse,
 health insurance
 meat and poultry (except for game meats, such as venison, ostrich,
and snake)
44
 The National Institutes of Health traces its roots to 1887, when a
one-room laboratory was created within the Marine Hospital
Service (MHS), predecessor agency to the U.S. Public Health Service
(PHS).
 The MHS had been established in 1798 to provide for the medical
care of merchant seamen. In the 1880s, the MHS had been charged
by Congress with examining passengers on arriving ships for clinical
signs of infectious diseases, especially for the dreaded diseases
cholera and yellow fever, in order to prevent epidemics.
45
MISSION
NIH’s mission is to seek fundamental knowledge about the
nature and behavior of living systems and the application of
that knowledge to enhance health, lengthen life, and
reduce the burdens of illness and disability.
46
 The goals of the agency are:
1. to foster fundamental creative discoveries, innovative research strategies, and
their applications as a basis for ultimately protecting and improving health;
2. to develop, maintain, and renew scientific human and physical resources that
will ensure the Nation's capability to prevent disease;
3. to expand the knowledge base in medical and associated sciences in order to
enhance the Nation's economic well-being
4. to exemplify and promote the highest level of scientific integrity, public
accountability, and social responsibility in the conduct of science
47
DRUG REGULATORY AGENCIES IN JAPAN
48
Agencies
 Ministry of Health and Welfare
 National Institute of Infectious Diseases
 National Institute of Health Sciences
49
History
In January 1938, the Ministry of Health and Welfare was established
by integrating the administrations of the Sanitary Bureau and the
Social Affairs Bureau in the Ministry of Home Affairs.
In September 1947 The Ministry of Labour was established by
integrating labour administrations that had previously been conducted
by the Ministry of Health and Welfare.
50
Make a Policy Regarding
1. Health and medical care-health, food, medical care, health
insurance
2. Children and childrearing
3. Long term care, health and welfare services
4. Employment security, labour
5. Pension
6. Other policy areas-international affairs, research project
51
MHLW IN JAPAN
 The Ministry of Health, Labor, and Welfare (MHLW) was
established by a merger of the Ministry of Health and Welfare
(MHW) and the Ministry of Labor, on January 6, 2001.
 The MHLW, which was originally established in 1938, has been in
charge of the improvement and promotion of social welfare, social
security and public health, and the new organization has the same
tasks.
 It consists of the ministry proper, affiliated institutions, councils,
local branches, and an external organization.
52
MHLW
Social insurance
agency
Ministry proper
Minister’s secretariat
Heath policy bureau
Heath service bureau
PFSB
Social welfare & war
victim’s relief bureau
Health and welfare
bureau for elderly
Equal employment
children & family
bureau
Insurance bureau
Pension bureau
Director general for
policy planning
53
 Social Welfare :
Services for elderly people
Services for persons with disabilities
 Social Security :
Pension systems that will ensure income in elderly age
Long term insurance to provide nursing care services
Public assistance systems that guarantee minimum standards.
54
Public Hygiene :
Appropriate medical services for diseases & injuries
Ensuring the safety of food, Water and medical supplies
Research into health science in order to make technological
advances
Maternal and child health
Job Security :
Promotion of employment
Employment of elderly people
Employment of persons with disabilities
Management of the employment insurance system
55
WORKING ENVIRONMENT
Policy planning to improve the working environment
Policy planning to ensure the health and safety of workers
Measurement to secure equal opportunity, equal treatment
Measures to support the harmonization of working and family
life
Management of the worker’s compensation system
56
HUMAN RESOURCES DEVELOPMENT
Promotion of human resources development that reacts to
changes in the industrial system
Encouragement of worker’s skill development under their own
initiative
Development of skilled human resources that support industrial
progress
57
Drug regulatory Agencies in EU
58
AGENCIES
 EU Legislation - Eudralex
 European Directorate for the Quality of Medicines and
Healthcare (EDQM)
 European Medicines Agency (EMEA)
 Heads of Medicines Agencies (HMA)
59
European Directorate For The Quality Of Medicines
& Health Care
The EDQM (Council of Europe) is a key European Organisation
involved in Harmonisation & Co-ordination of Standardisation,
Regulation & Quality Control of Medicines, Blood Transfusion, Organ
Transplantation, Pharmaceuticals and Pharmaceutical Care.
In 1996 The European Directorate for the Quality of Medicines (EDQM)
is created.
60
MISSION
To contribute to the basic human right of access to good quality medicines
and healthcare and to promote and protect human and animal health by:
Establishing and providing official standards which apply to the
manufacture and quality control of medicines in all signatory States of the
"Convention on the Elaboration of a European Pharmacopoeia" and beyond;
Ensuring the application of these official standards to substances used in the
production of medicines;
61
 Co-ordinating a network of Official Medicines Control Laboratories (OMCL) to
collaborate and share expertise among Member States and to effectively use
limited resources;
 Proposing ethical, safety and quality standards:
- for the collection, preparation, storage, distribution and appropriate use
of blood components in blood transfusion;
- for the transplantation of organs, tissues and cells;
62
ORGANIZATIONORGANIZATION
CHARTCHART
63
E M A
 EMA is a European agency for the evaluation of medicinal product.
 EMA was set up in 1995.
 From 1995 to 2004, EMA was known as European agency for the
evaluation of medicinal product.
 The European Medicines Agency (EMA) is a decentralized body of
the European Union, located in London
 Mission: to foster scientific excellence in evaluation and supervision
of medicines.
64
office of executive
director
Executive director
Legal service
Senior medical officer Internal audit
Information
and
communicat
e ion
veterinary
medicines
and product
data
management
Patient health
protection
Human
medicines
development
and
evaluation
65
ACTIVITIES OF EMA
 provides independent, science-based recommendations on the
quality, safety and efficacy of medicines.
 applies efficient and transparent evaluation procedures to help
bring new medicines to the market.
 implements measures for continuously supervising the quality,
safety and efficacy of authorised medicines.
 provides scientific advice to stimulate the development and
improve the availability of innovative new medicines;
66
recommends safe limits for residues of veterinary medicines used in
food-producing animals.
publishes impartial and comprehensible information about
medicines and their use;
develops best practice for medicines evaluation and supervision in
Europe, and contributes alongside the Member States and the
European Commission to the harmonization of regulatory standards at
the international level.
67
68
 The International Conference on Harmonisation of Technical Requirements forThe International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human UseRegistration of Pharmaceuticals for Human Use (ICH) is unique in bringing
together the regulatory authorities and pharmaceutical industry of Europe,
Japan and the US to discuss scientific and technical aspects of drug registration.
 Since its inception in 1990, ICH has evolved, through its ICH Global Cooperation
Group, to respond to the increasingly global face of drug development, so that
the benefits of international harmonization for better global health can be
realized worldwide.
 ICH's mission is to achieve greater harmonization to ensure that safe, effective,
and high quality medicines are developed and registered in the most resource-
efficient manner.
69
HISTORY
The Need to Harmonise
 The realization that it was important to have an independent
evaluation of medicinal products before they are allowed on the
market
 However in many cases the realization was driven by tragedies,
such as that with thalidomide in Europe in the 1960s.
 For most countries, whether or not they had initiated product
registration controls earlier, the 1960s and 1970s saw a rapid
increase in laws, regulations and guidelines for reporting and
evaluating the data on safety, quality and efficacy of new medicinal
products
70
Initiation of ICH
Harmonization of regulatory requirements was pioneered by the European
Community (EC), in the 1980s, as the EC (now the European Union) moved
towards the development of a single market for pharmaceuticals
At the same time there were bilateral discussions between Europe, Japan
and the US on possibilities for harmonization.
71
It was, however, at the WHO Conference of Drug Regulatory
Authorities (ICDRA), in Paris, in 1989, that specific plans for action
began to materialize.
Soon afterwards, the authorities approached IFPMA to discuss a
joint regulatory-industry initiative on international harmonization, and
ICH was conceived.
The birth of ICH took place at a meeting in April 1990, hosted by
EFPIA in Brussels
72
Objectives
 Better consumer information.
 Post marketing safety.
 New product review.
 Keep watch on safe manufacturing and handling.
 Monitoring for new risk.
 Standardization and regulation.
 Enforcement and corrective problem.
73
MissionMission
ICH’s mission is to make recommendations towards achieving
greater harmonization in the interpretation and application of
technical guidelines and requirements for pharmaceutical product
registration, thereby reducing or obviating duplication of testing
carried out during the research and development of new human
medicines.
74
 To maintain a forum for a constructive dialogue between
regulatory authorities and the pharmaceutical industry on the real
and perceived differences in the technical requirements for product
registration in the EU, USA and Japan in order to ensure a more
timely introduction of new medicinal products, and their
availability to patients.
MissionMission
75
To contribute to the protection of public health from an international perspective;
To monitor and update harmonised technical requirements leading to a greater
mutual acceptance of research and development data;
To avoid divergent future requirements through harmonization of selected topics
needed as a result of therapeutic advances and the development of new
technologies for the production of medicinal products;
To facilitate the adoption of new or improved technical research and development
approaches which update or replace current practices, where these permit a more
economical use of human, animal and material resources, without compromising
safety;
To facilitate the dissemination and communication of information on harmonised
guidelines and their use such as to encourage the implementation and integration of
common standards.
MissionMission
76
ICH STRUCTURE
The ICH is composed of the following components:
 Steering Committee,
 ICH Secretariat,
 Observers,
 Expert Working Group (EWG).
77
The ICH receives support from the following organizations:
 In the European Union, the European Agency for the Evaluation of
Medicinal Products (EMEA) and the European Federation of
Pharmaceutical Industries’ Associations (EFPIA) represent both
regulatory agencies and industry associations, respectively;
 In the United States, the Food and Drug Administration (FDA) and
Pharmaceutical Research and Manufacturers of America (PhRMA)
are included; and
 In Japan, the Ministry of Health, Labour, and Welfare (MHLW1) and
the Japan Pharmaceutical Manufacturers Association (JPMA) are
the respective organizations.
78
How does ICH work ?
 ICH operates through the ICH Steering Committee with administrative
support from the ICH Secretariat and ICH Coordinators.
 The Steering Committee meets at least twice a year, rotating meeting
sites among the three regions.
 The topics identified for harmonization by the Steering Committee are
selected.
 Working Groups also meet during the same week as the Steering
Committee meetings and report on their progress to the Committee.
Considerable work also occurs between meetings.
79
Current ICH Terms of Reference (2000)
 To maintain a forum for a constructive dialogue between regulatory authorities
and the pharmaceutical industry on the real and perceived differences in the
technical requirements for product registration in the EU, USA and Japan in order
to ensure a more timely introduction of new medicinal products, and their
availability to patients;
 To contribute to the protection of public health from an international
perspective;
 To monitor and update harmonized technical requirements leading to a greater
mutual acceptance of research and development data;
 To avoid divergent future requirements through harmonization of selected
topics needed as a result of therapeutic advances and the development of new
technologies for the production of medicinal products;
80
ICH GUIDELINES
The ICH topics are divided into four major categories:
A. Quality topics,
B. Safety topics,
C. Efficacy topics,
D. Multidisciplinary topics.
81
82
REFERENCES
1. www.cdsco.nic.in
2. www.mohfw.nic.in
3. www.health.cg.gov.in
4. www.icmr.nic.in
5. www.dst.gov.in
6. http://www.nppaindia.nic.in/index1.html
7. http://www.nihfw.org/
8. http://indianmedicine.nic.in/
9. http://www.nih.gov/
10. http://www.mhlw.go.jp/
11. http://www.edqm.eu
12. http://www.ich.org
13. http://www.infoahmedabad.com/2009/11/gujarat-fdca-to-set-up-6-more-district.html
83

More Related Content

What's hot

Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
 
Regulatory Affairs.
Regulatory Affairs.Regulatory Affairs.
Regulatory Affairs.Naila Kanwal
 
Clinical Trials in India
Clinical Trials in IndiaClinical Trials in India
Clinical Trials in Indiavaatsalya
 
US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.Venugopal N
 
USFDA GUIDLINES
USFDA GUIDLINESUSFDA GUIDLINES
USFDA GUIDLINESRaj Tiwari
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceMd. Zakaria Faruki
 
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)Vijay Banwala
 
clinical trial application in india
clinical trial application in indiaclinical trial application in india
clinical trial application in indiaRohit K.
 
UNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESSUNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESSKabin Maleku
 
Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australianandiniwarier93
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USAsandeep bansal
 
Regulatory authority of japan
Regulatory authority of japanRegulatory authority of japan
Regulatory authority of japanAadityaThole
 

What's hot (20)

Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.
 
Regulatory Affairs.
Regulatory Affairs.Regulatory Affairs.
Regulatory Affairs.
 
CDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATION
CDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATIONCDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATION
CDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATION
 
Clinical Trials in India
Clinical Trials in IndiaClinical Trials in India
Clinical Trials in India
 
US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.
 
USFDA GUIDLINES
USFDA GUIDLINESUSFDA GUIDLINES
USFDA GUIDLINES
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
 
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh AlemiPharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
 
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
 
clinical trial application in india
clinical trial application in indiaclinical trial application in india
clinical trial application in india
 
UNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESSUNDERSTANDING GENERIC VS INNOVATOR BUSINESS
UNDERSTANDING GENERIC VS INNOVATOR BUSINESS
 
Regulatory guidelines of Australia
Regulatory guidelines of AustraliaRegulatory guidelines of Australia
Regulatory guidelines of Australia
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
 
Anda
AndaAnda
Anda
 
Ich guidelines
Ich guidelinesIch guidelines
Ich guidelines
 
Regulatory approval and system of drug master file ,IND and NDA in USA
Regulatory approval and system of  drug master file ,IND  and NDA in USARegulatory approval and system of  drug master file ,IND  and NDA in USA
Regulatory approval and system of drug master file ,IND and NDA in USA
 
Regulatory authority of japan
Regulatory authority of japanRegulatory authority of japan
Regulatory authority of japan
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
 
Usfda
UsfdaUsfda
Usfda
 

Viewers also liked

Drug Regulatory Agencies.
 Drug Regulatory Agencies. Drug Regulatory Agencies.
Drug Regulatory Agencies.Priyanka Chakote
 
Drug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj DhapadeDrug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj DhapadePankaj Dhapade
 
Int health agencies
Int health agencies Int health agencies
Int health agencies DRRV
 
Voluntary agencies in health care delivery
Voluntary agencies in health care deliveryVoluntary agencies in health care delivery
Voluntary agencies in health care deliverySandhya rani Javalkar
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in euRajaniKarpur
 
Smu mba sem 4 common papers summer 2016 assignments
Smu mba sem 4 common papers summer 2016  assignmentsSmu mba sem 4 common papers summer 2016  assignments
Smu mba sem 4 common papers summer 2016 assignmentsPradeep Sharma
 
Quality certificates
Quality certificates Quality certificates
Quality certificates Asnad Ashraf
 
Regulation of drug sector in India
Regulation of drug sector in IndiaRegulation of drug sector in India
Regulation of drug sector in IndiaSharath Gowda
 
EFFECTS AND BENEFITS OF GLOBALISATION
EFFECTS AND BENEFITS OF GLOBALISATIONEFFECTS AND BENEFITS OF GLOBALISATION
EFFECTS AND BENEFITS OF GLOBALISATIONRB PRASAD
 
Health care agencies and their roles
Health care agencies and their rolesHealth care agencies and their roles
Health care agencies and their rolesNursing Path
 
International health agencies & current global health issues
International health agencies & current global health issuesInternational health agencies & current global health issues
International health agencies & current global health issuesAmrut Swami
 
TGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCATGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCASagar Savale
 
International Health Agency
International Health AgencyInternational Health Agency
International Health AgencyPurnima Radesh
 
International Health agency
International Health agencyInternational Health agency
International Health agencySujata Mohapatra
 
Export promotion scheme in india
Export promotion scheme in indiaExport promotion scheme in india
Export promotion scheme in indiakagil
 
Voluntary health agencies in india
Voluntary health agencies in indiaVoluntary health agencies in india
Voluntary health agencies in indiakarthika thangaraj
 
Role of voluntary health organization and international health agencies
Role of voluntary health organization and international health agenciesRole of voluntary health organization and international health agencies
Role of voluntary health organization and international health agenciesIndra Mani Mishra
 

Viewers also liked (20)

Types of FDI
Types of FDITypes of FDI
Types of FDI
 
Drug Regulatory Agencies.
 Drug Regulatory Agencies. Drug Regulatory Agencies.
Drug Regulatory Agencies.
 
Drug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj DhapadeDrug Regulatory Affairs By Mr. Pankaj Dhapade
Drug Regulatory Affairs By Mr. Pankaj Dhapade
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
Int health agencies
Int health agencies Int health agencies
Int health agencies
 
Voluntary agencies in health care delivery
Voluntary agencies in health care deliveryVoluntary agencies in health care delivery
Voluntary agencies in health care delivery
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in eu
 
Smu mba sem 4 common papers summer 2016 assignments
Smu mba sem 4 common papers summer 2016  assignmentsSmu mba sem 4 common papers summer 2016  assignments
Smu mba sem 4 common papers summer 2016 assignments
 
Quality certificates
Quality certificates Quality certificates
Quality certificates
 
Regulation of drug sector in India
Regulation of drug sector in IndiaRegulation of drug sector in India
Regulation of drug sector in India
 
Regulatory agency
Regulatory agencyRegulatory agency
Regulatory agency
 
EFFECTS AND BENEFITS OF GLOBALISATION
EFFECTS AND BENEFITS OF GLOBALISATIONEFFECTS AND BENEFITS OF GLOBALISATION
EFFECTS AND BENEFITS OF GLOBALISATION
 
Health care agencies and their roles
Health care agencies and their rolesHealth care agencies and their roles
Health care agencies and their roles
 
International health agencies & current global health issues
International health agencies & current global health issuesInternational health agencies & current global health issues
International health agencies & current global health issues
 
TGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCATGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCA
 
International Health Agency
International Health AgencyInternational Health Agency
International Health Agency
 
International Health agency
International Health agencyInternational Health agency
International Health agency
 
Export promotion scheme in india
Export promotion scheme in indiaExport promotion scheme in india
Export promotion scheme in india
 
Voluntary health agencies in india
Voluntary health agencies in indiaVoluntary health agencies in india
Voluntary health agencies in india
 
Role of voluntary health organization and international health agencies
Role of voluntary health organization and international health agenciesRole of voluntary health organization and international health agencies
Role of voluntary health organization and international health agencies
 

Similar to International Regulatory agencies

OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN Arul Packiadhas
 
The drugs and cosmetics act and rules cosmetics-mnz
The drugs and cosmetics act and rules  cosmetics-mnzThe drugs and cosmetics act and rules  cosmetics-mnz
The drugs and cosmetics act and rules cosmetics-mnzmaitreyi zaveri
 
Regulatory Control in Pharmaceutical Analysis
Regulatory Control in Pharmaceutical AnalysisRegulatory Control in Pharmaceutical Analysis
Regulatory Control in Pharmaceutical AnalysisDr Duggirala Mahendra
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agenciesShaik Sana
 
regulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfregulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfVhuii
 
Regulations, guidelines & ethics in clinical research
Regulations, guidelines & ethics in clinical researchRegulations, guidelines & ethics in clinical research
Regulations, guidelines & ethics in clinical researchDr. Harisha S
 
2. regulations overview
2. regulations overview2. regulations overview
2. regulations overviewDr. Harisha S
 
Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...
Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...
Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...Yamini Shah
 
Pharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of IndiaPharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of IndiaRutujaNale1
 
Bodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdscoBodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdscochiranjibi68
 
Drugs and cosmetics act 1940 and rules 1945 swa
Drugs and cosmetics act 1940 and rules 1945 swaDrugs and cosmetics act 1940 and rules 1945 swa
Drugs and cosmetics act 1940 and rules 1945 swaSuvarta Maru
 
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha Anup Soans
 
Indian Regulatory Requirements
Indian Regulatory RequirementsIndian Regulatory Requirements
Indian Regulatory RequirementsAudumbar Mali
 
Role of all the Govt. pharma regulator Bodies.pptx
Role of all the Govt. pharma regulator Bodies.pptxRole of all the Govt. pharma regulator Bodies.pptx
Role of all the Govt. pharma regulator Bodies.pptxnilimasakharkar1
 
Drugs & cosmetics act 1940
Drugs & cosmetics act 1940Drugs & cosmetics act 1940
Drugs & cosmetics act 1940Rakshit Thumar
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdfASSAM DOWN TOWN UNIVERSITY
 
Drugs and cosmetics Act 1940,schedules &rules and regulations
Drugs and cosmetics Act 1940,schedules &rules and regulationsDrugs and cosmetics Act 1940,schedules &rules and regulations
Drugs and cosmetics Act 1940,schedules &rules and regulationsM Swetha
 

Similar to International Regulatory agencies (20)

OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN
 
Regulatory bodies & CRO
Regulatory bodies & CRORegulatory bodies & CRO
Regulatory bodies & CRO
 
The drugs and cosmetics act and rules cosmetics-mnz
The drugs and cosmetics act and rules  cosmetics-mnzThe drugs and cosmetics act and rules  cosmetics-mnz
The drugs and cosmetics act and rules cosmetics-mnz
 
Regulatory Control in Pharmaceutical Analysis
Regulatory Control in Pharmaceutical AnalysisRegulatory Control in Pharmaceutical Analysis
Regulatory Control in Pharmaceutical Analysis
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
regulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfregulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdf
 
Regulations, guidelines & ethics in clinical research
Regulations, guidelines & ethics in clinical researchRegulations, guidelines & ethics in clinical research
Regulations, guidelines & ethics in clinical research
 
2. regulations overview
2. regulations overview2. regulations overview
2. regulations overview
 
Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...
Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...
Drug Store Licensing, Drug Regulatory Authority in India and Schedule Related...
 
Pharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of IndiaPharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of India
 
Bodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdscoBodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdsco
 
Drugs and cosmetics act 1940 and rules 1945 swa
Drugs and cosmetics act 1940 and rules 1945 swaDrugs and cosmetics act 1940 and rules 1945 swa
Drugs and cosmetics act 1940 and rules 1945 swa
 
Regulatory aspects
Regulatory aspectsRegulatory aspects
Regulatory aspects
 
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha
Pharma Malpractices - Report of the Parliament Committee to Rajya Sabha
 
Indian Regulatory Requirements
Indian Regulatory RequirementsIndian Regulatory Requirements
Indian Regulatory Requirements
 
Role of all the Govt. pharma regulator Bodies.pptx
Role of all the Govt. pharma regulator Bodies.pptxRole of all the Govt. pharma regulator Bodies.pptx
Role of all the Govt. pharma regulator Bodies.pptx
 
Drugs & cosmetics act 1940
Drugs & cosmetics act 1940Drugs & cosmetics act 1940
Drugs & cosmetics act 1940
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf
 
Madhu k s
Madhu k s Madhu k s
Madhu k s
 
Drugs and cosmetics Act 1940,schedules &rules and regulations
Drugs and cosmetics Act 1940,schedules &rules and regulationsDrugs and cosmetics Act 1940,schedules &rules and regulations
Drugs and cosmetics Act 1940,schedules &rules and regulations
 

International Regulatory agencies

  • 1. 1
  • 2. CONTENTS • Meaning • Introduction • Key function • Agencies in INDIA • Agencies in US • Agencies in JAPAN • Agencies in EU • ICH • References 2
  • 3. MEANING OF DRUG REGULATION • Drug “All medicines for internal or external use of human beings or animals and all substances intended to be used for diagnosis, treatment, mitigation or prevention of any disease or disorder in human beings or animals” • Regulation “To regulate means to control something so that it functions properly” 3
  • 4. INTRODUCTION Drugs play an important role in the health of both people and the economy of a country. Pharmaceutical drugs are available from a large number of sources. 4
  • 5. INTRODUCTION People and Governments willing to spend money on drugs for many reasons so, it must be safe, effective and good quality and used appropriately. This means, in turn, that development, production, importation, exportation and subsequent distribution of drugs must be regulated to ensure that they meet prescribed standards. 5
  • 6. INTRODUCTION • Therefore, effective drug regulation is required to ensure the safety, efficacy and quality of drugs as well as accuracy and appropriateness of the drug information available to the public. 6
  • 7. KEY FUNCTIONS OF DRUG REGULATORY AGENCY  Product registration (drug evaluation and authorization, and monitoring of drug efficacy and safety)  Regulation of drug manufacturing, importation, and distribution; 7
  • 8. KEY FUNCTIONS OF DRUG REGULATORY AGENCY  Regulation & Control of drug promotion and information.  Adverse drug reaction (ADR) monitoring.  Licensing of premises, persons and practices.  Main goal of drug regulation is to guarantee the safety, efficacy and quality of drugs available to public. 8
  • 9. THE DRUG REGULATION CONSISTS OF: 1. Drug Laws 2. Drug Regulatory Agencies 3. Drug Regulatory Boards 4. Quality Control 5. Drug Information Centers etc. 9
  • 10. DRUGS REGULATORY SYSTEM IN INDIA 10
  • 11. Drugs and Health is in concurrent list of Indian Constitution It is governed by both Centre and State Governments under the Drugs & Cosmetics Act, 1940. 11
  • 12. 12 MAIN BODIES:MAIN BODIES: * Central Drug Standard Control Organization (CDSCO) * Ministry Of Health & Family Welfare (MHFW)  Indian Council Of Medical Research (ICMR)  Indian Pharmaceutical Association (IPA)  Drug Technical Advisory Board (DTAB)  Central Drug Testing Laboratory (CDTL)  Indian Pharmacopoeia Commission (IPC)  National Pharmaceutical Pricing Authority (NPPA)
  • 13. INDIA – WELL DEFINED DRUG REGULATORY SYSTEM GOVT. of INDIA • Ministry of Health and Family Welfare DGHS CDSCO DCGI 13 DTAB  Enforcement & GMP audit Div  Quality Control Division – CDTL  Registration Div  New Drug Div Pharmacovigilance Trainings
  • 14. APPROVAL OF INVESTIGATIONAL NEW DRUG (IND) 14
  • 16. 16 16
  • 17. 17 17
  • 18. 18 Functions undertaken by Central GovernmentFunctions undertaken by Central Government Statutory FunctionStatutory Function 1. Laying down standards of drugs, cosmetics, diagnostics and devices. 2. Laying down regulatory measures, amendments to Acts and Rules. 3. To regulate market authorization of new drugs. 4. To regulate clinical research in India
  • 19. 19 1. To approve licenses to manufacture certain categories of drugs as Central Licence Approving Authority i.e. for Blood Banks, Large Volume Parenterals and Vaccines & Sera. 2. To regulate the standards of imported drugs. 3. Work relating to the Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committee (DCC). 4. Testing of drugs by Central Drugs Labs. 5. Publication of Indian Pharmacopoeia.
  • 20. 20 National Institute of Health and Family Welfare (NIHFW) NIHFW is an Apex Technical Institute, funded by Ministry of Health and Family Welfare, for promotion of health and family welfare programmers in the country through education, training, research, evaluation, consultancy and specialized services. The NIHFW was established on March 9, 1977 by a merger of the National Institute of Health Administration and Education (NIHAE) with the National Institute of Family Planning (NIFP).
  • 21. 21 List of Governing Body Members of NIHFW 18 members 1 Chairman (ex-officio) 1 Vice Chairman (ex-officio) 9 Member ( ex-officio) 6 Member 1 Member Secretary (ex-officio)
  • 22. 22 ACTIVITIES AND RESPONSIBILITIESACTIVITIES AND RESPONSIBILITIES  Measuring weight of children to assess the nutritional status.  Assessment of diseases like level of anemia.  Testing of food material like cooking salt for level iodine. To release fund on the advice of the Ministry.  It is responsible for all governmental programs relating to family planning in India.
  • 23. 23 STRUCTURE AND ORGANIZATION Union Health Minister Governing Body Scientific Advisory Board Scientific Advisory Groups Expert Groups Scientific Advisory Committee Steering Committee Task Forces
  • 24. 24 ACTIVITIES AND RESPONSIBILITIESACTIVITIES AND RESPONSIBILITIES  Extramural research is promoted by ICMR by establishing Centers for Advanced Research in different research areas.  The ICMR also funds task force studies which emphasize a time- bound, goal-oriented approach.
  • 25. 25  Open-ended research is conducted on the basis of applications for grants-in-aid received from scientists in non-ICMR Research Institutes, Medical colleges and Universities located in different parts of the country.  In the context of the changing public health scene.  Balancing of research efforts between different competing fields, especially when resources are severely limited, is a typical problem encountered in the management of medical research, particularly in developing countries.
  • 26. 26 DRUG TECHNICAL ADVISORY BOARD (DTAB) The Central Government constitute a Board (to be called the Drugs Technical Advisory Board) to advise the Central Government and the State Governments on technical matters arising out of the administration of D&C, Act 1940 The Board shall consist of the following members, 18 Members 10 ex-officio Members 5 Nominated Members 5 Elected Members
  • 27. 27 ACTIVITIES AND RESPONSIBILITIESACTIVITIES AND RESPONSIBILITIES  It advices matter related to Drugs.  The nominated and elected members of the Board shall hold office for three years, but shall be eligible for re-nomination and re- election.  The Board may, subject to the previous approval of the Central Government, make bye-laws fixing a quorum and regulating its own procedure.
  • 28. 28 CENTRAL DRUG TESTING LABORATORY (CDTL)  The central drug laboratory, Kolkata is national statutory laboratory of the government of India for quality control of drug and cosmetic and established under the D&C act ,1940.  Oldest quality control laboratory of the drug control authorities in India.  Function under the director general of Health Services in the Ministry of Health and Family Welfare.
  • 29. 29 FUNCTIONS UNDER TAKEN Statutory Function:  To Act as an Appellate authority.  To function as Government Analyst for such states who do not have their own testing facilities.  Analytical quality control of majority of the imported drugs.  Analytical quality control of drug formulations manufactured within the country on behalf of the Central & State Drug standard control organization
  • 30. 30 Other Functions  Procurement, establishment, maintenance, storage and distribution of I.P & International Reference standards.  Preparation and standardization of I.P. reference standards against USP, BP primary standards.  To undertake analytical research in standardization and methodology development of drug.
  • 31. 31 Indian Pharmacopoeia Commission (IPC) General Body 19 Members Governing Body 10 Members Scientific Body 23 Experts CIPL Lab IPC Secretariat Indian Pharmacopoeia was prepared by Indian Pharmacopoeia Commission(IPC)
  • 32. 32 ACTIVITIES AND RESPONSIBILITIES  Development of comprehensive monographs.  Accord priority to monographs of drugs included in the national Essential Drug List and their dosage forms.  Preparation of monograph for products that have normally been in the market for not less than 2 years.  Collaborate with pharmacopoeias like the BP, USP, JP and International Pharmacopoeia with a view to harmonizing with global standards.
  • 34. 34 AGENCIES  The Food and Drug Administration (FDA)  National Institutes of Health (NIH)  Centers for Disease Control and Prevention  Department of Health and Human Services (DHHS)
  • 35. 35  Fed World - US Government Information  National Center for Complementary and Alternative Medicine (NCCAM)  National Center for Infectious Diseases (NCID)  National Library of Medicine  National Science Foundation  Office of Disease Prevention
  • 36. 36 The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It consists of six product centers, one research center, and two offices. FDA’s responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions. Food and Drug Administration 10903 New Hampshire Ave Silver Spring, MD 20993-0002
  • 37. 37 HISTORY  1927 — The "Bureau of Chemistry" is reorganized into two separate entities. Regulatory functions are located in the "Food, Drug, and Insecticide Administration", and nonregulatory research is located in the "Bureau of Chemistry and Soils".  1930 — The name of the "Food, Drug, and Insecticide Administration" is shortened to "Food and Drug Administration" (FDA) under an agricultural appropriations act.
  • 38. 38 MISSION  The Food and Drug Modernization Act states that the FDA has 4 roles: To promote health by reviewing research and approving new products To ensure foods and drugs are safe and properly labeled To work with other nations to “reduce the burden of regulation” To cooperate with scientific experts and consumers to effectively carry out these obligations
  • 39. 39 ORGANIZATION  The agency currently has roughly 9,500 full-time employees and is headquartered in Rockville, Maryland. The agency’s total budget in financial year 2002 was about $1.4 billion (the federal government’s financial year begins in September).  The FDA is led by the Commissioner of Food and Drugs, who is appointed by the President and confirmed by the Senate.  Dr. Mark McClellan, a physician with a doctorate in economics, was nominated to be commissioner by President George W. Bush in September 2002 and confirmed by the Senate in October
  • 40. 40
  • 41. 41 FDA IS RESPONSIBLE FOR  Protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled;  Assuring human and veterinary drugs, and vaccines and other biological products and medical devices intended for human use are safe and effective  Protecting the public from electronic product radiation
  • 42. 42  Assuring cosmetics and dietary supplements are safe and properly labeled  Regulating tobacco products  Advancing the public health by helping to speed product innovations  Helping the public get the accurate science-based information they need to use medicines, devices, and foods to improve their health  Initiation of a Recall. Includes voluntary, FDA requested, and FDA mandated.
  • 43. 43 What doesn’t FDA regulate? FDA does not regulate:  advertising (except for prescription drugs, medical devices, and tobacco products)  alcoholic beverages  illegal drugs of abuse,  health insurance  meat and poultry (except for game meats, such as venison, ostrich, and snake)
  • 44. 44  The National Institutes of Health traces its roots to 1887, when a one-room laboratory was created within the Marine Hospital Service (MHS), predecessor agency to the U.S. Public Health Service (PHS).  The MHS had been established in 1798 to provide for the medical care of merchant seamen. In the 1880s, the MHS had been charged by Congress with examining passengers on arriving ships for clinical signs of infectious diseases, especially for the dreaded diseases cholera and yellow fever, in order to prevent epidemics.
  • 45. 45 MISSION NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.
  • 46. 46  The goals of the agency are: 1. to foster fundamental creative discoveries, innovative research strategies, and their applications as a basis for ultimately protecting and improving health; 2. to develop, maintain, and renew scientific human and physical resources that will ensure the Nation's capability to prevent disease; 3. to expand the knowledge base in medical and associated sciences in order to enhance the Nation's economic well-being 4. to exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science
  • 48. 48 Agencies  Ministry of Health and Welfare  National Institute of Infectious Diseases  National Institute of Health Sciences
  • 49. 49 History In January 1938, the Ministry of Health and Welfare was established by integrating the administrations of the Sanitary Bureau and the Social Affairs Bureau in the Ministry of Home Affairs. In September 1947 The Ministry of Labour was established by integrating labour administrations that had previously been conducted by the Ministry of Health and Welfare.
  • 50. 50 Make a Policy Regarding 1. Health and medical care-health, food, medical care, health insurance 2. Children and childrearing 3. Long term care, health and welfare services 4. Employment security, labour 5. Pension 6. Other policy areas-international affairs, research project
  • 51. 51 MHLW IN JAPAN  The Ministry of Health, Labor, and Welfare (MHLW) was established by a merger of the Ministry of Health and Welfare (MHW) and the Ministry of Labor, on January 6, 2001.  The MHLW, which was originally established in 1938, has been in charge of the improvement and promotion of social welfare, social security and public health, and the new organization has the same tasks.  It consists of the ministry proper, affiliated institutions, councils, local branches, and an external organization.
  • 52. 52 MHLW Social insurance agency Ministry proper Minister’s secretariat Heath policy bureau Heath service bureau PFSB Social welfare & war victim’s relief bureau Health and welfare bureau for elderly Equal employment children & family bureau Insurance bureau Pension bureau Director general for policy planning
  • 53. 53  Social Welfare : Services for elderly people Services for persons with disabilities  Social Security : Pension systems that will ensure income in elderly age Long term insurance to provide nursing care services Public assistance systems that guarantee minimum standards.
  • 54. 54 Public Hygiene : Appropriate medical services for diseases & injuries Ensuring the safety of food, Water and medical supplies Research into health science in order to make technological advances Maternal and child health Job Security : Promotion of employment Employment of elderly people Employment of persons with disabilities Management of the employment insurance system
  • 55. 55 WORKING ENVIRONMENT Policy planning to improve the working environment Policy planning to ensure the health and safety of workers Measurement to secure equal opportunity, equal treatment Measures to support the harmonization of working and family life Management of the worker’s compensation system
  • 56. 56 HUMAN RESOURCES DEVELOPMENT Promotion of human resources development that reacts to changes in the industrial system Encouragement of worker’s skill development under their own initiative Development of skilled human resources that support industrial progress
  • 58. 58 AGENCIES  EU Legislation - Eudralex  European Directorate for the Quality of Medicines and Healthcare (EDQM)  European Medicines Agency (EMEA)  Heads of Medicines Agencies (HMA)
  • 59. 59 European Directorate For The Quality Of Medicines & Health Care The EDQM (Council of Europe) is a key European Organisation involved in Harmonisation & Co-ordination of Standardisation, Regulation & Quality Control of Medicines, Blood Transfusion, Organ Transplantation, Pharmaceuticals and Pharmaceutical Care. In 1996 The European Directorate for the Quality of Medicines (EDQM) is created.
  • 60. 60 MISSION To contribute to the basic human right of access to good quality medicines and healthcare and to promote and protect human and animal health by: Establishing and providing official standards which apply to the manufacture and quality control of medicines in all signatory States of the "Convention on the Elaboration of a European Pharmacopoeia" and beyond; Ensuring the application of these official standards to substances used in the production of medicines;
  • 61. 61  Co-ordinating a network of Official Medicines Control Laboratories (OMCL) to collaborate and share expertise among Member States and to effectively use limited resources;  Proposing ethical, safety and quality standards: - for the collection, preparation, storage, distribution and appropriate use of blood components in blood transfusion; - for the transplantation of organs, tissues and cells;
  • 63. 63 E M A  EMA is a European agency for the evaluation of medicinal product.  EMA was set up in 1995.  From 1995 to 2004, EMA was known as European agency for the evaluation of medicinal product.  The European Medicines Agency (EMA) is a decentralized body of the European Union, located in London  Mission: to foster scientific excellence in evaluation and supervision of medicines.
  • 64. 64 office of executive director Executive director Legal service Senior medical officer Internal audit Information and communicat e ion veterinary medicines and product data management Patient health protection Human medicines development and evaluation
  • 65. 65 ACTIVITIES OF EMA  provides independent, science-based recommendations on the quality, safety and efficacy of medicines.  applies efficient and transparent evaluation procedures to help bring new medicines to the market.  implements measures for continuously supervising the quality, safety and efficacy of authorised medicines.  provides scientific advice to stimulate the development and improve the availability of innovative new medicines;
  • 66. 66 recommends safe limits for residues of veterinary medicines used in food-producing animals. publishes impartial and comprehensible information about medicines and their use; develops best practice for medicines evaluation and supervision in Europe, and contributes alongside the Member States and the European Commission to the harmonization of regulatory standards at the international level.
  • 67. 67
  • 68. 68  The International Conference on Harmonisation of Technical Requirements forThe International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseRegistration of Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry of Europe, Japan and the US to discuss scientific and technical aspects of drug registration.  Since its inception in 1990, ICH has evolved, through its ICH Global Cooperation Group, to respond to the increasingly global face of drug development, so that the benefits of international harmonization for better global health can be realized worldwide.  ICH's mission is to achieve greater harmonization to ensure that safe, effective, and high quality medicines are developed and registered in the most resource- efficient manner.
  • 69. 69 HISTORY The Need to Harmonise  The realization that it was important to have an independent evaluation of medicinal products before they are allowed on the market  However in many cases the realization was driven by tragedies, such as that with thalidomide in Europe in the 1960s.  For most countries, whether or not they had initiated product registration controls earlier, the 1960s and 1970s saw a rapid increase in laws, regulations and guidelines for reporting and evaluating the data on safety, quality and efficacy of new medicinal products
  • 70. 70 Initiation of ICH Harmonization of regulatory requirements was pioneered by the European Community (EC), in the 1980s, as the EC (now the European Union) moved towards the development of a single market for pharmaceuticals At the same time there were bilateral discussions between Europe, Japan and the US on possibilities for harmonization.
  • 71. 71 It was, however, at the WHO Conference of Drug Regulatory Authorities (ICDRA), in Paris, in 1989, that specific plans for action began to materialize. Soon afterwards, the authorities approached IFPMA to discuss a joint regulatory-industry initiative on international harmonization, and ICH was conceived. The birth of ICH took place at a meeting in April 1990, hosted by EFPIA in Brussels
  • 72. 72 Objectives  Better consumer information.  Post marketing safety.  New product review.  Keep watch on safe manufacturing and handling.  Monitoring for new risk.  Standardization and regulation.  Enforcement and corrective problem.
  • 73. 73 MissionMission ICH’s mission is to make recommendations towards achieving greater harmonization in the interpretation and application of technical guidelines and requirements for pharmaceutical product registration, thereby reducing or obviating duplication of testing carried out during the research and development of new human medicines.
  • 74. 74  To maintain a forum for a constructive dialogue between regulatory authorities and the pharmaceutical industry on the real and perceived differences in the technical requirements for product registration in the EU, USA and Japan in order to ensure a more timely introduction of new medicinal products, and their availability to patients. MissionMission
  • 75. 75 To contribute to the protection of public health from an international perspective; To monitor and update harmonised technical requirements leading to a greater mutual acceptance of research and development data; To avoid divergent future requirements through harmonization of selected topics needed as a result of therapeutic advances and the development of new technologies for the production of medicinal products; To facilitate the adoption of new or improved technical research and development approaches which update or replace current practices, where these permit a more economical use of human, animal and material resources, without compromising safety; To facilitate the dissemination and communication of information on harmonised guidelines and their use such as to encourage the implementation and integration of common standards. MissionMission
  • 76. 76 ICH STRUCTURE The ICH is composed of the following components:  Steering Committee,  ICH Secretariat,  Observers,  Expert Working Group (EWG).
  • 77. 77 The ICH receives support from the following organizations:  In the European Union, the European Agency for the Evaluation of Medicinal Products (EMEA) and the European Federation of Pharmaceutical Industries’ Associations (EFPIA) represent both regulatory agencies and industry associations, respectively;  In the United States, the Food and Drug Administration (FDA) and Pharmaceutical Research and Manufacturers of America (PhRMA) are included; and  In Japan, the Ministry of Health, Labour, and Welfare (MHLW1) and the Japan Pharmaceutical Manufacturers Association (JPMA) are the respective organizations.
  • 78. 78 How does ICH work ?  ICH operates through the ICH Steering Committee with administrative support from the ICH Secretariat and ICH Coordinators.  The Steering Committee meets at least twice a year, rotating meeting sites among the three regions.  The topics identified for harmonization by the Steering Committee are selected.  Working Groups also meet during the same week as the Steering Committee meetings and report on their progress to the Committee. Considerable work also occurs between meetings.
  • 79. 79 Current ICH Terms of Reference (2000)  To maintain a forum for a constructive dialogue between regulatory authorities and the pharmaceutical industry on the real and perceived differences in the technical requirements for product registration in the EU, USA and Japan in order to ensure a more timely introduction of new medicinal products, and their availability to patients;  To contribute to the protection of public health from an international perspective;  To monitor and update harmonized technical requirements leading to a greater mutual acceptance of research and development data;  To avoid divergent future requirements through harmonization of selected topics needed as a result of therapeutic advances and the development of new technologies for the production of medicinal products;
  • 80. 80 ICH GUIDELINES The ICH topics are divided into four major categories: A. Quality topics, B. Safety topics, C. Efficacy topics, D. Multidisciplinary topics.
  • 81. 81
  • 82. 82 REFERENCES 1. www.cdsco.nic.in 2. www.mohfw.nic.in 3. www.health.cg.gov.in 4. www.icmr.nic.in 5. www.dst.gov.in 6. http://www.nppaindia.nic.in/index1.html 7. http://www.nihfw.org/ 8. http://indianmedicine.nic.in/ 9. http://www.nih.gov/ 10. http://www.mhlw.go.jp/ 11. http://www.edqm.eu 12. http://www.ich.org 13. http://www.infoahmedabad.com/2009/11/gujarat-fdca-to-set-up-6-more-district.html
  • 83. 83